Nitrous Oxide for the Treatment of Complex Regional Pain Syndrome
Status:
Enrolling by invitation
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Patients will then be randomized via a web-based randomization system Redcap Allocation will
be stratified based on the presence of a pre-existing spinal cord stimulator to either the
nitrous oxide study group or the oxygen control group.
The nitrous oxide group will receive 50% nitrous oxide mixed with 50% oxygen, and the control
group will receive 50% oxygen (oxygen plus air mixture). Both groups will undergo inhalation
therapy for a duration of 2 hours via an FDA-approved mask breathing circuit. Vital signs
(blood pressure, respiratory rate, heart rate) will be monitored every 30 minutes. Pulse
oximetry monitoring will be continuous. Patients will be monitored for side effects including
nausea, vomiting, desaturation, sedation, respiratory depression, and dizziness. Patients and
other involved providers will be blinded to the treatment type.